Figure 4From: The cost-effectiveness of neonatal screening for Cystic Fibrosis: an analysis of alternative scenarios using a decision modelIncremental cost-effectiveness (£/QALY) of neonatal screening for cystic fibrosis compared with no screening, assuming different cost discount rates and assumed effects of preventive therapy.Back to article page